Lipoflux, 30 Serve - Strawberry Lychee

  • Sale
  • Regular price $74.95
Tax included.


Lipoflux is an advanced fat loss targeting support formula combining first to market innovative complexes and clinically researched herbal extracts. Through adopting advanced pharmaceutics our complexes have been formulated and prepared by our own chemist aiming to directly optimize the active components as well as indirectly enhance the entire formula. The combination of these ingredients is both complementary and synergistic in supporting the major processes for accessing and using stored fat energy during a calorie deficit, whilst also supporting energy, mood and appetite.

Sabianine A HCl / Origanum Vulgare Extract 100mg/10mg:

“The fat cell is like a bank: a place to store excess (caloric) in times of plenty, and from which one can withdraw savings during ‘lean times’...” ) -Collins (2012)

The β-adrenoceptors are one of the key biological gateways to the mobilization of stored fat. (1)

This Vanguard Science first to market complex is included with intent to exploit this pathway. Tinospora Crispa contains a spectrum of polyhydroxylated benzylisoquinoline alkaloids bearing experimental and clinical evidence indicating the capacity to activate the β-adrenoceptors. (2-6)

These alkaloids appear to have very short biologically active effects when administered as the plant extract or as solo isolated ingredients alone- which may significantly limit the desired effects.

Vanguard Science tackles this issue with unique innovation, using a complexation with a terpene extract of Origanum Vulgare. This complex may selectively and potently inhibit one major arm of the alkaloids metabolism aiming to extend both the amount that can be used as well as the time in which it can be used. 

L-Ornithine

Caffeine is widely consumed and well known for stimulating the central nervous system. When developing new foods and beverages that contain caffeine, it is important to explore the potential synergistic effects of consuming amino acids and other food ingredients with caffeine on humans.

Given the physiological pathways affected by the amino acid ornithine, consumption of ornithine with caffeine may have synergistic effects. In a 2014 study, (Research Laboratories for Health Science & Food Technologies, Kirin Company Ltd., Yokohama 236-0004, Japan.) researchers examined the effect of consuming caffeine with ornithine in humans. The study used a randomized, placebo-controlled, double-blinded crossover design. The subjects were all healthy office workers who ingested the placebo, 100 mg caffeine, or 100 mg caffeine plus 200 mg ornithine in the morning and completed questionnaires about their mood. Office workers who consumed the combination of caffeine and ornithine had higher mood ratings 8 h after consumption than office workers who consumed caffeine alone. The results of the present study suggest that there is a unique synergistic effect between caffeine and ornithine on the mood of healthy office workers and that ornithine may potentiate the effects of caffeine.

Theobroma Cacao Extract (Fatty Acid Fraction) 200mg

This unique component is included with an aim to support energy balance through appetite regulation and by augmenting beta-adrenergic fat mobilizing and utilization.

The lipid fraction of Theobroma Cacao extract contains a spectrum of fatty acids that mimic signalling amides that naturally occur in the body (7).

One of these fatty acid amides, and ethanolamide, has been demonstrated to be a key regulating agent that, among other beneficial targets that regulate energy homeostasis, can turn on satiety mechanisms at the gastrointestinal, liver and (indirectly) at brain level (8-11) . Evidence indicates that the production of this fatty acid amide naturally surges upon feeding (12). It is suggested this compound may exert these effects by acting as a very potent activator of PPAR‐α and fatty acid translocase and by increasing dopamine signalling through oxytocin and histamine (9-11,13). Through the former of these targets, it has also demonstrated to stimulate lipolysis and fatty acid oxidation and to enhance beta-receptor mediated energy expenditure in fat tissue (13-14).

Anemarrhena asphodeloides Extract /Hydroxypropyl betacyclodextrin 1130mg

This industry first Vanguard Science complex is used with the aim to augment and regulate the psychostimulant and energy effects of the caffeine component as well as the delay the breakdown of the Tinospora alkaloids.

The C-glycoside tetrahydroxyxanthone fractions contained at high levels in Anemarrhena bear experimental and clinical evidence demonstrating capacity to both augment adrenergic and dopaminergic signalling through inhibiting a common metabolic pathway for these neurotransmitters as well as other compounds. (15-20) It is believed that it is through this pathway that this extract can provide central nervous stimulatory actions as well as augment other actions of the plant extract. (15-18)

This same pathway is common for both the downstream signalling that gives caffeine stimulant-like actions as well as the breakdown of the alkaloids in Tinospora Crispa. (19-23)

These type of xanthone molecules found in Anemarrhena asphodeloides extract are notoriously non-soluble- which can affect bioavailability and other kinetic parameters such as mucosal permeability. (24,25)

Cyclodextrin complexation presents a special ability to form a stable unity with a variety of guest molecules enabling increasing solubility, stability, and bioavailability of certain hydrophobic compounds. The Vanguard Science exclusive complexation mimics that which has been proven in numerous preclinical trials. (23-26)

Undaria pinnatifida extract 100mg

This unique extract aims to complement the complete formula by amplifiying the terminal steps in accessing and utilizing stored fat as energy.

This marine plant contains a spectrum of xanthophyll carotenoids (27)- some of which hold direct clinical evidence demonstrating capacity to increase resting energy expenditure (28) . A high concentration of a specific xanthophyll can be found in Undaria pinnatifida which is characterized by a very unique molecular structure that sees the body metabolize it differently to other unique types of carotenoids (29-31). The actions of this parent carotenoid as well as the production and tissue storage of the unique metabolites is purported to be paramount the clinically evaluated anti-obesity effects that see it distinct from other molecules in it’s class (27,29-34).  The metabolites have been shown to potentially increase the gene expression of fat metabolizing enzymes (3&6) and the parent carotenoid may directly stimulate uncoupling protein-1 expression in fat tissue (34,35). This protein holds a key regulatory role in the amount of energy release in fat tissue as heat and it production may prolong the lipolysis instigated by beta-adrenergic signalling (36).  

Capsicum Annum (fractionated C18 perlargonic acid) 20mg

This specific component has been included in the Lipoflux formula with an aim to increase the presence of the natural beta-receptor ligand noradrenalin, to produce a prolonged second and third phase activation of these receptors so as to increase energy expenditure and increase fat oxidation .

Evidence that capsaicinoid ingestion may have desirable metabolic outcomes via increasing energy expenditure and fat oxidation (37-40,51). Capsaicinoids can bind to Transient Receptor Potential Vanilloid-1 receptor (TRPV1) a nerve channel that is primarily involved with pain signalling(40,43-44). Upon activation of this channel a signal produces a signal through the spinal cord (45) and then outward from the brain leading to an increase in noradrenaline and dopamine release from the adrenal medulla (42,45-46). Noradrenaline can then bind β-adrenergic receptors increasing expenditure and thermogenic activity (45-47). 

The pungency of many capsaicinoids is such that both acute and prolonged use can inevitably cause gastric distress (49). The fraction of Capsicum Anuum extract within Lipoflux uses a non-pungent analogue with a 18 carbon akyl side chain. This analogue does not cause gastric distress- as the extended length of the alkyl side chain alters the solubility and causes differential dynamic binding at the TRPV1 (43-44,50-52). The desired effects mediated through TPRV1 of this analogue remains equipotent to that of pungent capsaicinoids with shorter side chains (51).  

(1) Collins, S. (2012). β-Adrenoceptor signaling networks in adipocytes for recruiting stored fat and energy expenditure. Frontiers in endocrinology2, 102.
(2) Ahmad, W., Jantan, I., & Bukhari, S. N. (2016). Tinospora crispa (L.) Hook. f. & Thomson: a review of its ethnobotanical, phytochemical, and pharmacological aspects. Frontiers in pharmacology7, 59.
(3) Fukuda, N., Yonemitsu, M., & Kimura, T. (1983). Studies on the constituents of the stems of Tinospora tuberculata Beumee. I. N-trans-and N-cis-feruloyl tyramine, and a new phenolic glucoside, Tinotuberide. Chemical and Pharmaceutical Bulletin31(1), 156-161.
(4) Sun, D., Han, Y., Wang, W., Wang, Z., Ma, X., Hou, Y., & Bai, G. (2016). Screening and identification of Caulis Sinomenii bioactive ingredients with dual‐target NF‐κB inhibition and β2‐AR agonizing activities. Biomedical Chromatography30(11), 1843-1853.
(5) Praman, S., Mulvany, M. J., Williams, D. E., Andersen, R. J., & Jansakul, C. (2012). Hypotensive and cardio-chronotropic constituents of Tinospora crispa and mechanisms of action on the cardiovascular system in anesthetized rats. Journal of ethnopharmacology140(1), 166-178.
(6) Praman, S., Mulvany, M. J., Williams, D. E., Andersen, R. J., & Jansakul, C. (2013). Crude extract and purified components isolated from the stems of Tinospora crispa exhibit positive inotropic effects on the isolated left atrium of rats. Journal of ethnopharmacology149(1), 123-132.
(7) Di Marzo, V., Bisogno, T., Melck, D., Ross, R., Brockie, H., Stevenson, L., ... & De Petrocellis, L. (1998). Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS letters436(3), 449-454.
(8) Serrano, A., Pavón, F. J., Tovar, S., Casanueva, F., Señarís, R., Diéguez, C., & de Fonseca, F. R. (2011). Oleoylethanolamide: effects on hypothalamic transmitters and gut peptides regulating food intake. Neuropharmacology60(4), 593-601.
(9) De Fonseca, F. R., Navarro, M., Gomez, R., Escuredo, L., Nava, F., Fu, J., ... & Piomelli, D. (2001). An anorexic lipid mediator regulated by feeding. Nature414(6860), 209-212. 

(10) Gaetani, S., Fu, J., Cassano, T., Dipasquale, P., Romano, A., Righetti, L., ... & Piomelli, D. (2010). The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin. Journal of Neuroscience, 30(24), 8096-8101.
(11) Tellez, L. A., Medina, S., Han, W., Ferreira, J. G., Licona-Limón, P., Ren, X., ... & De Araujo, I. E. (2013). A gut lipid messenger links excess dietary fat to dopamine deficiency. Science, 341(6147), 800-802.
(12) Fu, J., Gaetani, S., Oveisi, F., Verme, J. L., Serrano, A., De Fonseca, F. R., ... & Piomelli, D. (2003). Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature, 425(6953), 90-93.
(13) Guzmán, M., Verme, J. L., Fu, J., Oveisi, F., Blázquez, C., & Piomelli, D. (2004). Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α). Journal of biological chemistry, 279(27), 27849-27854.
(14) Suárez, J., Rivera, P., Arrabal, S., Crespillo, A., Serrano, A., Baixeras, E., ... & de Fonseca, F. R. (2014). Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Disease models & mechanisms, 7(1), 129-141.
(15) Bhattacharya, S. K., Ghosal, S., Chaudhuri, R. K., & Sanyal, A. K. (1972). Canscora decussata (Gentianaceae) xanthones III: Pharmacological studies. Journal of pharmaceutical sciences, 61(11), 1838-1840.
(16) Bhattacharya, S. K. (1972). Monoamine oxidase-inhibiting activity of mangiferin isolated from Canscora decussata. Naturwissenschaften 59, 651. –65
(17) Lin, C. N., CHUNG, M. I., Arisawa, M., Shimizu, M., & Morita, N. (1984). The Constituents of Tripterospermum taiwanenes Satake var. alpinum Stake and Pharmacological Activity of Some Xanthone Derivatives. Pharmacognosy magazine, 38(1), p80-82.
(18) Ghosal, S., & Chaudhuri, R. K. (1973). New tetraoxygenated xanthones of Canscora decussata. Phytochemistry, 12(8), 2035-2038.
(19) Dimitrov, M., Nikolova, I., Benbasat, N., Kitanov, G., & Danchev, N. (2011). Acute toxicity, antidepressive and MAO inhibitory activity of mangiferin isolated from Hypericum aucheri. Biotechnology & Biotechnological Equipment, 25(4), 2668-2671.
(20) Gnerre, C., Thull, U., Gaillard, P., Carrupt, P. A., Testa, B., Fernandes, E., ... & Cruciani, G. (2001). Natural and synthetic xanthones as monoamine oxidase inhibitors: biological assay and 3D‐QSAR. Helvetica Chimica Acta, 84(3), 552-570.
(21) Fisone, G., Borgkvist, A., & Usiello, A. (2004). Caffeine as a psychomotor stimulant: mechanism of action. Cellular and Molecular Life Sciences CMLS, 61(7), 857-872.
(22) Okano, M., Sato, M., & Kageyama, S. (2017). Determination of higenamine and coclaurine levels in human urine after the administration of a throat lozenge containing Nandina domestica fruit. Drug testing and analysis, 9(11-12), 1788-1793.
(23) da Rocha Ferreira, F., Valentim, I. B., Ramones, E. L. C., Trevisan, M. T. S., Olea-Azar, C., Perez-Cruz, F., ... & Goulart, M. O. F. (2013). Antioxidant activity of the mangiferin inclusion complex with β-cyclodextrin. LWT-Food Science and Technology, 51(1), 129-134.
(24) Yang, X., Zhao, Y., Chen, Y., Liao, X., Gao, C., Xiao, D., ... & Yang, B. (2013). Host–guest inclusion system of mangiferin with β-cyclodextrin and its derivatives. Materials Science and Engineering: C, 33(4), 2386-2391.
(25) Peter, N., Majumdar, J., Biswas, G., Pawar, H. S., Mitra, A., & Mitra, A. (2017). Effects of mangiferin isolated from Mangifera indica leaves and evaluation of biologic activities of β-cyclodextrin-mangiferin complex particularly its antidiabetic and hypolipidaemic properties on type 1 diabetes rat model. Int J Herb Med, 5, 92-98.
(26) Wang, Z. P., Deng, J. G., Wang, Q., Li, X. J., & Wei, H. X. (2008). Improvement in the solubility of mangiferin by HP-β-CD inclusion. Chin Tradit Patent Med.
(27) Terasaki, M., Narayan, B., Kamogawa, H., Nomura, M., Stephen, N. M., Kawagoe, C., ... & Miyashita, K. (2012). Carotenoid profile of edible Japanese seaweeds: an improved HPLC method for separation of major carotenoids. Journal of Aquatic Food Product Technology, 21(5), 468-479.
(28) Abidov, M., Ramazanov, Z., Seifulla, R., & Grachev, S. (2010). The effects of Xanthigen™ in the weight management of obese premenopausal women with non‐alcoholic fatty liver disease and normal liver fat. Diabetes, obesity and metabolism, 12(1), 72-81.
(29) Hashimoto, T., Ozaki, Y., Taminato, M., Das, S. K., Mizuno, M., Yoshimura, K., ... & Kanazawa, K. (2009). The distribution and accumulation of fucoxanthin and its metabolites after oral administration in mice. British journal of nutrition, 102(2), 242-248.
(30) Asai, A., Yonekura, L., & Nagao, A. (2008). Low bioavailability of dietary epoxyxanthophylls in humans. British journal of nutrition, 100(2), 273-277.
(31) Mordenti, J. (1986). Man versus beast: pharmacokinetic scaling in mammals. Journal of pharmaceutical sciences, 75(11), 1028-1040.
(32) Yim, M. J., Hosokawa, M., Mizushina, Y., Yoshida, H., Saito, Y., & Miyashita, K. (2011). Suppressive effects of amarouciaxanthin A on 3T3-L1 adipocyte differentiation through down-regulation of PPARγ and C/EBPα mRNA expression. Journal of agricultural and food chemistry, 59(5), 1646-1652.
(33) Woo, M. N., Jeon, S. M., Kim, H. J., Lee, M. K., Shin, S. K., Shin, Y. C., ... & Choi, M. S. (2010). Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose concentration in high-fat fed C57BL/6N mice. Chemico-Biological Interactions, 186(3), 316-322.
(34) Maeda, H., Hosokawa, M., Sashima, T., Funayama, K., & Miyashita, K. (2005). Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochemical and biophysical research communications, 332(2), 392-397.
(35) Miyashita, K., Maeda, H., Okada, T., Abe, M., & Hosokawa, M. (2010). Functional food Anti-obesity and anti-diabetic effects of allenic carotenoid, fucoxanthin. Agro Food Industry Hi-Tech, 21(6), 24.
(36) Ahmadian, M., Duncan, R. E., & Sul, H. S. (2009). The skinny on fat: lipolysis and fatty acid utilization in adipocytes. Trends in Endocrinology & Metabolism, 20(9), 424-428.
(37) YOSHIOKA, M., LIM, K., KIKUZATO, S., KIYONAGA, A., TANAKA, H., SHINDO, M., & SUZUKI, M. (1995). Effects of red-pepper diet on the energy metabolism in men. Journal of nutritional science and vitaminology, 41(6), 647-656.
(38) Lejeune, M. P., Kovacs, E. M., & Westerterp-Plantenga, M. S. (2003). Effect of capsaicin on substrate oxidation and weight maintenance after modest body-weight loss in human subjects. British Journal of Nutrition, 90(3), 651-659.
(39) Rogers, J., Urbina, S. L., Taylor, L. W., Wilborn, C. D., Purpura, M., Jäger, R., & Juturu, V. (2018). Capsaicinoids supplementation decreases percent body fat and fat mass: Adjustment using covariates in a post hoc analysis. BMC obesity, 5(1), 1-10.
(40) Kawada, T., Watanabe, T., Takaishi, T., Tanaka, T., & Iwai, K. (1986). Capsaicin-induced β-adrenergic action on energy metabolism in rats: influence of capsaicin on oxygen consumption, the respiratory quotient, and substrate utilization. Proceedings of the Society for Experimental Biology and Medicine, 183(2), 250-256.
(41) Christie, S., Wittert, G. A., Li, H., & Page, A. J. (2018). Involvement of TRPV1 channels in energy homeostasis. Frontiers in endocrinology, 9, 420..
(42) Schattschneider, J., Zum Buttel, I., Binder, A., Wasner, G., Hedderich, J., & Baron, R. (2007). Mechanisms of adrenosensitivity in capsaicin induced hyperalgesia. European Journal of Pain, 11(7), 756-763.
(43) Baskaran, P., Covington, K., Bennis, J., Mohandass, A., Lehmann, T., & Thyagarajan, B. (2018). Binding efficacy and thermogenic efficiency of pungent and nonpungent analogs of capsaicin. Molecules, 23(12), 3198.
(44) Ursu, D., Knopp, K., Beattie, R. E., Liu, B., & Sher, E. (2010). Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity. European journal of pharmacology, 641(2-3), 114-122.
(45) Longhurst, J. C., Kaufman, M. P., Ordway, G. A., & Musch, T. I. (1984). Effects of bradykinin and capsaicin on endings of afferent fibers from abdominal visceral organs. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 247(3), R552-R559.
(46) Watanabe, T., Kawada, T., Yamamoto, M., & Iwai, K. (1987). Capsaicin, a pungent principle of hot red pepper, evokes catecholamine secretion from the adrenal medulla of anesthetized rats. Biochemical and biophysical research communications, 142(1), 259-264.
(47) Saito, M. (2015). Capsaicin and related food ingredients reducing body fat through the activation of TRP and brown fat thermogenesis. Advances in Food and Nutrition Research, 76, 1-28.
(48) Akbar, A., Yiangou, Y., Facer, P., Walters, J. R., Anand, P., & Ghosh, S. (2008). Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut, 57(7), 923-929.
(49) van Avesaat, M., Troost, F. J., Westerterp-Plantenga, M. S., Helyes, Z., Le Roux, C. W., Dekker, J., ... & Keszthelyi, D. (2016). Capsaicin-induced satiety is associated with gastrointestinal distress but not with the release of satiety hormones, 2. The American journal of clinical nutrition, 103(2), 305-313.
(50) Kobata, K., Saito, K., Tate, H., Nashimoto, A. K. I., Okuda, H., Takemura, I., ... & Watanabe, T. (2010). Long-chain N-vanillyl-acylamides from Capsicum oleoresin. Journal of agricultural and food chemistry, 58(6), 3627-3631.
(51) Inoue, N., Matsunaga, Y., Satoh, H., & Takahashi, M. (2007). Enhanced energy expenditure and fat oxidation in humans with high BMI scores by the ingestion of novel and non-pungent capsaicin analogues (capsinoids). Bioscience, biotechnology, and biochemistry, 71(2), 380-389.